About Zerion

Zerion Pharma

Zerion is a pharmaceutical development company aspiring to transform the pharmaceutical landscape with a new formulation technology, Dispersome®, that enables poorly soluble drugs to reach their true therapeutic potential.

The company was established in 2019 as a spinout from the University of Copenhagen based on a decade of research. Zerion is focused on improving existing drug products by building an internal pipeline while partnering with established pharmaceutical companies to solve their most challenging drug solubility problems.

Mission

We are on a mission to close a gap between discovery and development of novel drugs

Vision

We are dedicated to develop pharmaceutical products and technologies that improve lives and deliver exceptional value to our customers and shareholders

Zerion Pharma team

Management Team

Ole Wiborg

CEO, Co-Founder

Ole has more than 25 years executive experience in the pharma and biotech industry. He has prepared and negotiated numerous licensing and collaboration deals at all levels and is the co-founder of five companies in the life science/medtech field. In 2016 he co-founded and led the medtech company Cura Nordic until a successful exit in 2018 by way of an asset deal to Karo Pharma AB in Sweden.

Korbinian Löbmann

CSO, Co-Founder

Korbinian has a strong track record in pharmaceutical formulation and drug delivery with more than 10 years of experience in solid formulation and dosage form development, including preformulation, formulation, processing and manufacturing together with the relevant solid state characterization and quality control.

Jakob Dynnes Hansen

CFO

Jakob is an experienced executive with more than 20 years of experience as chief financial officer in the biotech industry and 9 years in investment banking.

Wei Tian

Vice President, CMC Development

Wei has a strong pharma track record with more than 20 years of experience working with pharmaceutical development at some of the leading players within drug delivery and formulation development, including Lonza, Catalent and Glide Pharma.

Mónica González Heredia

Vice President, Regulatory Affairs

Mónica is a pharma regulatory expert with more than 15 years experience within the multinational pharmaceutical industry, where she has held a number of regulatory positions of increasing responsibility.

Board of Directors

Torsten Goesch

Chairman of Board

Torsten is an experienced life science venture capital investor and has been a partner and director at Rosetta Capital since 2002. Dr. Goesch is also the founder and former managing director of TRG invest, a Munich-based consultancy serving companies in the life science sector.

Ole Wiborg

CEO, Co-Founder

Ole has more than 25 years executive experience in the pharma and biotech industry. He has prepared and negotiated numerous licensing and collaboration deals at all levels and is the co-founder of five companies in the life science/medtech field. In 2016 he co-founded and led the medtech company Cura Nordic until a successful exit in 2018 by way of an asset deal to Karo Pharma AB in Sweden.

Lars Lykke Thomsen

Board member

Lars is an experienced life sciences and pharmaceutical executive with a strong clinical and scientific background. He has 20 years of R&D experience from the pharmaceutical industry including CROs providing strategic and operational leadership in drug development programs and 20 years of management experience in pharmaceutical companies.

Jorrit Water

Co-Founder

Jorrit is an experienced scientist with +5 years of experience from the pharmaceutical industry within oral formulation and manufacturing technologies in preclinical R&D.